PL2952177T3 - Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p) - Google Patents

Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p)

Info

Publication number
PL2952177T3
PL2952177T3 PL15173766T PL15173766T PL2952177T3 PL 2952177 T3 PL2952177 T3 PL 2952177T3 PL 15173766 T PL15173766 T PL 15173766T PL 15173766 T PL15173766 T PL 15173766T PL 2952177 T3 PL2952177 T3 PL 2952177T3
Authority
PL
Poland
Prior art keywords
sphingosine
phosphate
compositions
receptor modulators
modulators
Prior art date
Application number
PL15173766T
Other languages
English (en)
Inventor
Colleen Ruegger
Michael Ambuehl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2952177(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2952177T3 publication Critical patent/PL2952177T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL15173766T 2007-10-12 2008-10-09 Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p) PL2952177T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12
EP15173766.5A EP2952177B1 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP12155251.7A EP2465492B1 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine I phosphate (sip) receptor modulators
PCT/US2008/079264 WO2009048993A2 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP08838495A EP2209493A2 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

Publications (1)

Publication Number Publication Date
PL2952177T3 true PL2952177T3 (pl) 2021-07-19

Family

ID=40032615

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15173766T PL2952177T3 (pl) 2007-10-12 2008-10-09 Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p)
PL12155251T PL2465492T3 (pl) 2007-10-12 2008-10-09 Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12155251T PL2465492T3 (pl) 2007-10-12 2008-10-09 Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)

Country Status (33)

Country Link
US (6) US8673918B2 (pl)
EP (7) EP3733162A1 (pl)
JP (2) JP6034000B2 (pl)
KR (3) KR101710845B1 (pl)
CN (1) CN101820916A (pl)
AR (1) AR068986A1 (pl)
AU (1) AU2008310846C1 (pl)
BR (1) BRPI0818161B8 (pl)
CA (2) CA2925175A1 (pl)
CL (1) CL2008003003A1 (pl)
CO (1) CO6270342A2 (pl)
DK (1) DK2952177T3 (pl)
EC (1) ECSP10010169A (pl)
ES (2) ES2545361T3 (pl)
HK (1) HK1213768A1 (pl)
HR (1) HRP20150838T1 (pl)
HU (2) HUE053835T2 (pl)
IL (3) IL204514B (pl)
JO (2) JOP20080436B1 (pl)
MA (1) MA31799B1 (pl)
MX (1) MX337152B (pl)
MY (1) MY159358A (pl)
NZ (1) NZ600355A (pl)
PE (2) PE20130309A1 (pl)
PL (2) PL2952177T3 (pl)
PT (2) PT2465492E (pl)
RU (1) RU2010118457A (pl)
SG (2) SG187458A1 (pl)
SI (2) SI2465492T1 (pl)
TN (1) TN2010000136A1 (pl)
TW (1) TW200927142A (pl)
WO (1) WO2009048993A2 (pl)
ZA (1) ZA201001819B (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800208A (zh) 2008-03-17 2015-07-29 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
US20110144082A1 (en) 2008-08-18 2011-06-16 David Leppert Compounds for the treatment of peripheral neuropathies
ME03594B (me) * 2008-12-22 2020-07-20 Novartis Ag Režim doziranja agonista s1p receptora
KR101660555B1 (ko) 2008-12-22 2016-09-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 요법
EP2560618A1 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH Melt-granulated fingolimod
US20130102682A1 (en) * 2010-04-22 2013-04-25 Ratiopharm Gmbh Fingolimod in the form of a solid solution
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
WO2012093161A1 (en) * 2011-01-07 2012-07-12 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2739272A1 (en) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
WO2013057212A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2996681B1 (en) * 2013-05-13 2019-12-18 Synthon B.V. Pharmaceutical composition comprising fingolimod
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6679495B2 (ja) * 2014-04-10 2020-04-15 ノバルティス アーゲー 免疫抑制製剤
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CN106999501B (zh) * 2014-11-17 2021-08-13 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
JP6680297B2 (ja) * 2015-04-28 2020-04-15 アステラス製薬株式会社 経口投与用医薬組成物
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
EP3355863A4 (en) * 2015-10-02 2019-06-19 Mylan, Inc STABLE FORMULATIONS OF FINGOLIMOD
MA44725A (fr) * 2016-04-22 2019-02-27 Incyte Corp Formulations d'un inhibiteur de lsd1
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
US11648197B2 (en) 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN117202893A (zh) * 2021-04-14 2023-12-08 株式会社Lg化学 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008943A1 (en) * 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
IL121625A (en) 1995-12-28 2001-09-13 Welfide Corp Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use
EP2030614A1 (en) 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
PT1319651E (pt) 1997-04-04 2005-09-30 Mitsubishi Pharma Corp Composto 2-aminopropano-1,3-diol, sua utilizacao farmaceutica e seus intermediarios sinteticos
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
CA2472713C (en) 2002-01-18 2011-07-19 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
EP2617711A1 (en) 2002-09-19 2013-07-24 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivatives, salts thereof and immunosuppressive agents
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
PE20131352A1 (es) * 2003-04-08 2013-11-14 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
AR044402A1 (es) 2003-05-19 2005-09-14 Irm Llc Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CA2778126A1 (en) 2003-06-24 2005-01-13 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
CN103193822A (zh) 2003-08-28 2013-07-10 诺瓦提斯公司 氨基丙醇衍生物
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US8633161B2 (en) 2005-03-24 2014-01-21 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
CN1891212B (zh) 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
WO2008037421A2 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator

Also Published As

Publication number Publication date
US20160296481A1 (en) 2016-10-13
SI2465492T1 (sl) 2015-12-31
BRPI0818161B1 (pt) 2020-12-22
WO2009048993A3 (en) 2010-05-06
AR068986A1 (es) 2009-12-23
PT2952177T (pt) 2021-04-26
HRP20150838T1 (hr) 2015-11-06
IL255737B (en) 2020-10-29
US20150165046A1 (en) 2015-06-18
ECSP10010169A (es) 2010-06-29
EP3733161A1 (en) 2020-11-04
JP2015091822A (ja) 2015-05-14
RU2010118457A (ru) 2011-11-20
DK2952177T3 (da) 2021-04-26
SG187458A1 (en) 2013-02-28
CA2699788A1 (en) 2009-04-16
BRPI0818161B8 (pt) 2021-05-25
EP2952177B1 (en) 2021-01-20
RU2016138157A (ru) 2018-12-13
PE20090799A1 (es) 2009-07-20
PT2465492E (pt) 2015-10-15
EP2653154A1 (en) 2013-10-23
RU2016138157A3 (pl) 2020-02-10
EP3733162A1 (en) 2020-11-04
CA2925175A1 (en) 2009-04-16
US20140142192A1 (en) 2014-05-22
TN2010000136A1 (en) 2011-09-26
EP2465492A1 (en) 2012-06-20
JOP20080436B1 (ar) 2023-03-28
CO6270342A2 (es) 2011-04-20
MY159358A (en) 2016-12-30
AU2008310846C1 (en) 2022-10-06
KR20100091179A (ko) 2010-08-18
AU2008310846A1 (en) 2009-04-16
US8673918B2 (en) 2014-03-18
ZA201001819B (en) 2010-12-29
BRPI0818161A2 (pt) 2017-05-16
WO2009048993A2 (en) 2009-04-16
SI2952177T1 (sl) 2021-07-30
IL204514B (en) 2018-01-31
KR20170021904A (ko) 2017-02-28
EP2465492B1 (en) 2015-07-01
KR101600098B1 (ko) 2016-03-04
IL277999A (en) 2020-11-30
EP3120833A1 (en) 2017-01-25
CL2008003003A1 (es) 2009-05-15
KR20160025633A (ko) 2016-03-08
US20170368001A1 (en) 2017-12-28
TW200927142A (en) 2009-07-01
PE20130309A1 (es) 2013-03-30
NZ600355A (en) 2013-02-22
IL255737A (en) 2018-01-31
KR101710845B1 (ko) 2017-02-27
ES2864671T3 (es) 2021-10-14
AU2008310846B2 (en) 2012-06-21
HK1213768A1 (zh) 2016-07-15
MA31799B1 (fr) 2010-10-01
EP2952177A1 (en) 2015-12-09
ES2545361T3 (es) 2015-09-10
HUE053835T2 (hu) 2021-07-28
US20100267675A1 (en) 2010-10-21
MX2010003925A (es) 2010-05-05
MX337152B (es) 2016-02-15
JP2011500583A (ja) 2011-01-06
JP6034000B2 (ja) 2016-11-30
JOP20210187A1 (ar) 2023-01-30
CN101820916A (zh) 2010-09-01
SG10201800085XA (en) 2018-02-27
CA2699788C (en) 2016-06-14
HUE027696T2 (en) 2016-10-28
EP2209493A2 (en) 2010-07-28
PL2465492T3 (pl) 2015-11-30
US20170151195A1 (en) 2017-06-01
US9399066B2 (en) 2016-07-26

Similar Documents

Publication Publication Date Title
IL277999A (en) Compounds containing modulators of the sphingosine 1 phosphate (S1P) receptor
HUS2000038I1 (hu) Szfingozin foszfát receptor új modulátorai
HK1214758A1 (zh) 用於治療多發硬化症的 受體調節劑
SI3103448T1 (sl) Farmacevtski sestavek, ki vsebuje modulator S1P
HK1213873A1 (zh) 選擇性的雜環 -磷酸鞘氨醇受體調節劑
HK1157146A1 (en) Composition for regulating lipid metabolism
IL209306A (en) Compounds 1, 2, 4 - Oxadiazole as modulators of sphingosine phosphate receptors
EP2178539A4 (en) PHOSPHOLIPIDE COMPREHENSIVE COMPOSITIONS
GB0722340D0 (en) Sphingosine-1-phosphate (S1P) receptor compounds
GB0610311D0 (en) Bisphosphonate formulation